DHODH Inhibitor Pipeline

DelveInsight’s “DHODH Inhibitor Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the DHODH Inhibitor Pipeline Landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the DHODH Inhibitors Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

DHODH Inhibitor Pipeline Understanding: Overview

Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as Acute Myeloid Leukemia, Rheumatoid Arthritis, and Multiple Sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 Treatment using DHODH inhibitors.

DHODH Inhibitors Pipeline Report Highlights

The DHODH Inhibitors Companies and academics are working to assess challenges and seek opportunities that could influence DHODH Inhibitor R&D. The DHODH Inhibitors Therapies under development are focused on novel approaches for DHODH Inhibitor.

DHODH Inhibitor Emerging Drugs Chapters

This segment of the DHODH Inhibitor Pipeline Report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand DHODH Inhibitors Clinical Trials details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

DHODH Inhibitor Emerging Drugs

 

• IMU-838: Immunic

IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.

 

• PTC 299: PTC Therapeutics

Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.

Further product details are provided in the report……..

DHODH Inhibitor Pipeline Therapeutic Assessment

This segment of the report provides insights about the different DHODH Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major DHODH Inhibitors Companies

There are approx. 10+ key companies which are developing the DHODH Inhibitor. The DHODH Inhibitors Companies that have their DHODH Inhibitor drug candidates in the most advanced stage, i.e. Phase II/III include, Immunic

Phases

DelveInsight’s DHODH Inhibitors Pipeline Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

DHODH Inhibitor Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

DHODH Inhibitors Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

DHODH Inhibitor Pipeline Development Activities

The DHODH Inhibitors Pipeline Report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Therapeutic drugs key DHODH Inhibitors Companies involved in developing key drugs.

 

Pipeline Development Activities

The DHODH Inhibitors Pipeline Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DHODH Inhibitor drugs.

DHODH Inhibitor Pipeline Report Insights

• DHODH Inhibitor Pipeline Analysis
• Therapeutic Assessment
• DHODH Inhibitors Unmet Needs
• Impact of DHODH Inhibitor Drugs

DHODH Inhibitor Pipeline Report Assessment

• DHODH Inhibitors Pipeline Product Profiles
• Therapeutic Assessment
• DHODH Inhibitors Pipeline Assessment
• Inactive DHODH Inhibitors Drugs Assessment
• DHODH Inhibitors Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing DHODH Inhibitor Drugs?
• How many DHODH Inhibitor Drugs are developed by each company?
• How many emerging drugs are in the mid-stage, and late-stage of development for DHODH Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DHODH Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the DHODH Inhibitors Clinical Trials going on and their status?
• What are the key designations that have been granted to the DHODH Inhibitors Emerging Drugs?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs